Current and historical daily PE Ratio for Fennec Pharmaceuticals Inc (
) from 1990 to May 28 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Fennec Pharmaceuticals stock (STU:RV41) PE ratio as of May 28 2024 is 194.89.
More Details
Fennec Pharmaceuticals Inc (STU:RV41) PE Ratio (TTM) Chart
Fennec Pharmaceuticals Inc (STU:RV41) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1247
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Fennec Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-28 | 240.0 | 2024-03-21 | At Loss |
| 2024-05-27 | 240.0 | 2024-03-20 | At Loss |
| 2024-05-24 | 244.0 | 2024-03-19 | At Loss |
| 2024-05-23 | 252.0 | 2024-03-18 | At Loss |
| 2024-05-22 | 262.0 | 2024-03-15 | At Loss |
| 2024-05-21 | 260.0 | 2024-03-14 | At Loss |
| 2024-05-20 | 268.0 | 2024-03-13 | At Loss |
| 2024-05-17 | 256.0 | 2024-03-12 | At Loss |
| 2024-05-16 | 248.0 | 2024-03-11 | At Loss |
| 2024-05-15 | 300.0 | 2024-03-08 | At Loss |
| 2024-05-14 | 268.0 | 2024-03-07 | At Loss |
| 2024-05-13 | 368.0 | 2024-03-06 | At Loss |
| 2024-05-10 | 344.0 | 2024-03-05 | At Loss |
| 2024-05-09 | 346.0 | 2024-03-04 | At Loss |
| 2024-05-08 | 346.0 | 2024-03-01 | At Loss |
| 2024-05-07 | 336.0 | 2024-02-29 | At Loss |
| 2024-05-06 | 340.0 | 2024-02-28 | At Loss |
| 2024-05-03 | 344.0 | 2024-02-27 | At Loss |
| 2024-05-02 | 334.0 | 2024-02-26 | At Loss |
| 2024-04-30 | 342.0 | 2024-02-23 | At Loss |
| 2024-04-29 | 334.0 | 2024-02-22 | At Loss |
| 2024-04-26 | 338.0 | 2024-02-21 | At Loss |
| 2024-04-25 | 326.0 | 2024-02-20 | At Loss |
| 2024-04-24 | 338.0 | 2024-02-19 | At Loss |
| 2024-04-23 | 342.0 | 2024-02-16 | At Loss |
| 2024-04-22 | 346.0 | 2024-02-15 | At Loss |
| 2024-04-19 | 348.0 | 2024-02-14 | At Loss |
| 2024-04-18 | 358.0 | 2024-02-13 | At Loss |
| 2024-04-17 | 370.0 | 2024-02-12 | At Loss |
| 2024-04-16 | 382.0 | 2024-02-09 | At Loss |
| 2024-04-15 | 384.0 | 2024-02-08 | At Loss |
| 2024-04-12 | 398.0 | 2024-02-07 | At Loss |
| 2024-04-11 | 404.0 | 2024-02-06 | At Loss |
| 2024-04-10 | 390.0 | 2024-02-05 | At Loss |
| 2024-04-09 | 388.0 | 2024-02-02 | At Loss |
| 2024-04-08 | 398.0 | 2024-02-01 | At Loss |
| 2024-04-05 | 398.0 | 2024-01-31 | At Loss |
| 2024-04-04 | 392.0 | 2024-01-30 | At Loss |
| 2024-04-03 | 400.0 | 2024-01-29 | At Loss |
| 2024-04-02 | 396.0 | 2024-01-26 | At Loss |
| 2024-03-28 | 412.0 | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
Fennec Pharmaceuticals Inc (STU:RV41) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Fennec Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA31447P1009
Description
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers